Mechanism of action, clinical effectiveness, and optimal therapeutic range

被引：360
作者：
Hirsh, J [1 ]
Dalen, JE [1 ]
Anderson, DR [1 ]
Poller, L [1 ]
Bussey, H [1 ]
Ansell, J [1 ]
Deykin, D [1 ]
Brandt, JT [1 ]
机构：
[1] Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada
来源：
CHEST | 1998年 / 114卷 / 05期
关键词：
D O I：
10.1378/chest.114.5_Supplement.445S
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：445S / 469S
页数：25
相关论文
共 250 条
[31]  
BROEKMANS AW, 1983, THROMB HAEMOSTASIS, V49, P251
[32]   HEMOSTATIC DEFECT PRODUCED BY CARBENICILLIN [J].
BROWN, CH ;
NATELSON, EA ;
BRADSHAW, MW ;
WILLIAMS, TW ;
ALFREY, CP .
NEW ENGLAND JOURNAL OF MEDICINE, 1974, 291 (06) :265-270
[33]   RELIANCE ON PROTHROMBIN TIME RATIOS CAUSES SIGNIFICANT ERRORS IN ANTICOAGULATION THERAPY [J].
BUSSEY, HI ;
FORCE, RW ;
BIANCO, TM ;
LEONARD, AD .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (02) :278-282
[34]  
BUSSEY HI, 1989, PHARMACOTHERAPY, V9, P214
[35]   ANTITHROMBOTIC AGENTS IN CORONARY-ARTERY DISEASE [J].
CAIRNS, JA ;
HIRSH, J ;
LEWIS, HD ;
RESNEKOV, L ;
THEROUX, P .
CHEST, 1992, 102 (04) :S456-S481
[36]   OPTIMAL ORAL ANTICOAGULANT-THERAPY IN PATIENTS WITH MECHANICAL HEART-VALVES [J].
CANNEGIETER, SC ;
ROSENDAAL, FR ;
WINTZEN, AR ;
VANDERMEER, FJM ;
VANDENBROUCKE, JP ;
BRIET, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (01) :11-17
[37]  
CAZENAVE JP, 1973, P SOC EXP BIOL MED, V142, P159
[38]  
CHANTARANGKUL V, 1995, THROMB HAEMOSTASIS, V73, P1237
[39]   ANTICOAGULATION CLINICS AND THE MONITORING OF ANTICOAGULANT-THERAPY [J].
CHARNEY, R ;
LEDDOMADO, E ;
ROSE, DN ;
FUSTER, V .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 1988, 18 (02) :197-206
[40]   TRIAL OF COMBINED WARFARIN PLUS DIPYRIDAMOLE OR ASPIRIN THERAPY IN PROSTHETIC HEART-VALVE REPLACEMENT - DANGER OF ASPIRIN COMPARED WITH DIPYRIDAMOLE [J].
CHESEBRO, JH ;
FUSTER, V ;
ELVEBACK, LR ;
MCGOON, DC ;
PLUTH, JR ;
PUGA, FJ ;
WALLACE, RB ;
DANIELSON, GK ;
ORSZULAK, TA ;
PIEHLER, JM ;
SCHAFF, HV .
AMERICAN JOURNAL OF CARDIOLOGY, 1983, 51 (09) :1537-1541
12345678910